IRCT20120215009014N335 IRCT 2020-01-20 Hamedan University of Medical Sciences Effect of Fingolimod with and without probiotic and vitamin E on the liver complications of in patients with relapsing-remitting multiple sclerosis Effect of Fingolimod with and without probiotic and vitamin E on the liver complications of in patients with relapsing-remitting multiple sclerosis: a double-blind randomized clinical trial 2020-04-03 anticipated 80 Complete https://irct.ir/trial/44877 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The patients will be randomly assigned to intervention and control groups using block randomization. For this purpose, we will prepare four sheets of paper, writing on two sheets the name of the intervention and on the other two sheets the name of the control. The paper sheets will be pooled, placed in a container, and randomly drawn one at a time for each patient without replacement until all four sheets are drawn. The four paper sheets will be then placed back into the container, and this action repeated until the sample size is reached, Blinding description: The drugs will be given in coded envelops. Therefore, patients will be unaware of the type of intervention. The physician who will examine the patients will not be aware of the intervention. The analyzer will be unaware of the type of interventions Thus, the trial will be run as triple-blind. 2 Multiple sclerosis. Intervention 1: Intervention group 1: Fingolimod capsule 0.5 mg (manufactured by Razavi Pharmaceutical Co.) daily and LactoCare probiotic capsule (manufactured by Pardis Technology Park Co.) daily for 2 months. Intervention 2: Intervention group 2:Fingolimod capsule 0.5 mg (manufactured by Razavi Pharmaceutical Co.) daily and Perl Vitamin E 100 units (manufactured by Zahravi Pharmaceuticals Co.) daily for 2 Months. Intervention 3: Intervention group 3:Fingolimod capsule 0.5 mg (manufactured by Razavi Pharmaceutical Co.) daily and LactoCare probiotic capsule (manufactured by Pardis Technology Park Co.) daily and Perl Vitamin E 100 units (manufactured by Zahravi Pharmaceutical Co.) daily for 2 months. Intervention 4: Control group:Fingolimod capsule 0.5 mg (manufactured by Razavi Pharmaceutical Co.) daily for 2 months. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is It depends on the situations and the results of the study as well as the approval of the financial supporting organization.